Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Tyrosine-Protein Kinase Receptor Ufo (Axl Oncogene; Ec=2.7.10.1)); Humanized Monoclonal Antibody Conjugated To The Pyrrolobenzodiazepine (Pdb) Dimer, Sg3199; .Gamma.1 Heavy Chain Humanized (1-451) (Vh Humanized (Homo Sapiens Ighv3-30*03 (93%)-(Ighd)-Ighj4*01 (92%)) (8.8.15) (1-122) Homo Sapiens Ighg1*03 (Ch1(R97>K(219)), Ch3(K107>Del(452))) (123-451)), (225-215')-Disulfide With .Kappa. Light Chain Humanized (1'-215') (Humanized V-Kappa (Homo Sapiens Igkv3-11*01 (84%)-Igkj4*01 (91%))(7.3.9) (1'-108')-Homo Sapiens Igkc*01 (109'-215')); Dimer (231-231'':234-234'')-Bisdisulfide, Produced In Chinese Cho Cells, Glycoform Alfa; Conjugated On The Two Glycoengineered Asn-302 And Asn-302'', Via A Spacer And Cleavable Valyl-Alanyl Linker, To The Cytotoxic Pyrrolobenzodiazepine (Pbd) Dimer, Sg3199
Cancer
Explore 1,379 assets in Cancer →Floatz Rating
C36/100
Confidence
Indicative
Sponsor
ADC Therapeutics S.A.
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05389462CT.gov A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT03700294CT.gov Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Tyrosine-Protein Kinase Receptor Ufo (Axl Oncogene; Ec=2.7.10.1)); Humanized Monoclonal Antibody Conjugated To The Pyrrolobenzodiazepine (Pdb) Dimer, Sg3199; .Gamma.1 Heavy Chain Humanized (1-451) (Vh Humanized (Homo Sapiens Ighv3-30*03 (93%)-(Ighd)-Ighj4*01 (92%)) (8.8.15) (1-122) Homo Sapiens Ighg1*03 (Ch1(R97>K(219)), Ch3(K107>Del(452))) (123-451)), (225-215')-Disulfide With .Kappa. Light Chain Humanized (1'-215') (Humanized V-Kappa (Homo Sapiens Igkv3-11*01 (84%)-Igkj4*01 (91%))(7.3.9) (1'-108')-Homo Sapiens Igkc*01 (109'-215')); Dimer (231-231'':234-234'')-Bisdisulfide, Produced In Chinese Cho Cells, Glycoform Alfa; Conjugated On The Two Glycoengineered Asn-302 And Asn-302'', Via A Spacer And Cleavable Valyl-Alanyl Linker, To The Cytotoxic Pyrrolobenzodiazepine (Pbd) Dimer, Sg3199 (this asset) | ADC Therapeutics S.A. | P1 | C · 36 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P4 | BB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Fluorouracilum | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | InSilico Medicine Hong Kong Limited | P4 | BB |
| Trametinib | Cancer Research UK | P2/3 | BB |
+42 more in the Cancer cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Tyrosine-Protein Kinase Receptor Ufo (Axl Oncogene; Ec=2.7.10.1)); Humanized Monoclonal Antibody Conjugated To The Pyrrolobenzodiazepine (Pdb) Dimer, Sg3199; .Gamma.1 Heavy Chain Humanized (1-451) (Vh Humanized (Homo Sapiens Ighv3-30*03 (93%)-(Ighd)-Ighj4*01 (92%)) (8.8.15) (1-122) Homo Sapiens Ighg1*03 (Ch1(R97>K(219)), Ch3(K107>Del(452))) (123-451)), (225-215')-Disulfide With .Kappa. Light Chain Humanized (1'-215') (Humanized V-Kappa (Homo Sapiens Igkv3-11*01 (84%)-Igkj4*01 (91%))(7.3.9) (1'-108')-Homo Sapiens Igkc*01 (109'-215')); Dimer (231-231'':234-234'')-Bisdisulfide, Produced In Chinese Cho Cells, Glycoform Alfa; Conjugated On The Two Glycoengineered Asn-302 And Asn-302'', Via A Spacer And Cleavable Valyl-Alanyl Linker, To The Cytotoxic Pyrrolobenzodiazepine (Pbd) Dimer, Sg3199 in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-tyrosine-protein-kinase-receptor-ufo-axl-oncogene-ec27101-humanized-monoclonal-antibody-conjugated-to-the-pyrrolobenzodiazepine-pdb-dimer-sg3199-gamma1-heavy-chain-humanized-1-451-vh-humanized-homo-sapiens-ighv3-3003-93-ighd-ighj401-92-8815-1-122-homo-sapiens-ighg103-ch1r97k219-ch3k107del452-123-451-225-215-disulfide-with-kappa-light-chain-humanized-1-215-humanized-v-kappa-homo-sapiens-igkv3-1101-84-igkj401-91739-1-108-homo-sapiens-igkc01-109-215-dimer-231-231234-234-bisdisulfide-produced-in-chinese-cho-cells-glycoform-alfa-conjugated-on-the-two-glycoengineered-asn-302-and-asn-302-via-a-spacer-and-cleavable-valyl-alanyl-linker-to-the-cytotoxic-pyrrolobenzodiazepine-pbd-dimer-sg3199-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →